May 17, 2024
5 min watch
Save
VIDEO: ARVO highlights AI’s role in age-related macular degeneration
SEATTLE — In this video, Eleonora M. Lad, MD, PhD, vice chair of ophthalmology clinical research at Duke Health, discusses highlights in age-related macular degeneration from the ARVO meeting.
Highlights included research on oral nutrients, diets, the reduction of treatment burden and the use of AI. AI in clinical trials for retinal diseases, AI for the quantification of fluid segmentation in wet AMD and AI that helps with clinical trial endpoints were hot topics of discussion at the meeting, Lad said.
“The use of artificial intelligence, machine learning algorithms, are currently helping us. They play a crucial role in detecting, classifying and predicting the course of the disease,” she said. “This is a huge area of unmet need too because no algorithm has been currently approved by the FDA for management of AMD.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Lad reports serving as a scientific advisor for 4DMT, Alexion, Allegro, Annexon, Apellis, Aspen Neuroscience, Blue Rock, Boehringer Ingelheim, Broadwing Bio, Complement Therapeutics, Emmecell, Galimedix, IMI-2 Consortium, Iveric Bio/Astellas, Janssen, Kriya Therapeutics, LumiThera, Lutronic Vision, Nanoscope Therapeutics, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Osanni Bio, Perceive Bio, Regeneron, Retrotope, Roche, Sanofi and Thea Laboratoires; receiving research funding from Alexion, Apellis, Belite Bio, Boehringer Ingelheim, Gemini Therapeutics, Iveric Bio, Janssen, LumiThera, Neurotech, NGM Biopharmaceuticals, NIH/NEI K23, Novartis, Research to Prevent Blindness, Roche and VA CSR&D I01; owning stock options in Osanni Bio; and having provisional patent 63162741: “A system and method to predict progression of age-related macular degeneration.”